Biocad Files Lawsuit Against Roche Over Anti-Competitive Pricing Practices

June 15, 2016

Biopharmaceutical firm Biocad has filed suit against Roche and its Genentech subsidiary over their alleged use of predatory pricing practices in Russia intended to decimate the sales of the Russian drugmaker’s biosimilars.

Roche intentionally operated at a loss in Russia for three of its oncology drugs — Avastin, Herceptin and Rituxan — after Biocad successfully created biosimilars for all of them, according to the lawsuit filed in the U.S. District Court for the Southern District of New York.

By selling the treatments below market rates in Russia, Roche would destroy Biocad’s operations and prevent it from bringing cheaper biosimilars to the U.S. market while profiting from the higher prices in America, the lawsuit states.

View today's stories